151751-Najiba-Chargi

271 Systemic therapy: the prospective PLATISMA study 14. Urien S, Lokiec F. Population pharmacoki - netics of total and unbound plasma cispla- tin in adult patients. Br J Clin Pharmacol . 2004;57(6):756-763. doi:10.1111/j.1365- 2125.2004.02082.x 15. Swartz JE, Pothen AJ, Wegner I, et al. Feasibility of using head and neck CT im - aging to assess skeletal muscle mass in head and neck cancer patients. Oral Oncol . 2016;62:28-33. doi:10.1016/j.oraloncolo - gy.2016.09.006 16. Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol . 2017;71:26-33. doi:10.1016/j.oraloncology.2017.05.012 17. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdom- inal cross-sectional image. J Appl Physiol . 2004;97:2333-2338. doi:10.1152/japplphysi - ol.00744.2004. 18. Ward SR, Lieber RL. Density and hydration of fresh and fixed human skeletal muscle. J Biomech . 2005;38:2317-2320. doi:10.1016/j. jbiomech.2004.10.001 19. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of Lean Bodyweight. Clin Pharmacokinet . 2005;44(10):1051-1065. 20. Brouwers EEM, Tibben MM, Rosing H, et al. Sensitive inductively coupled plasma mass spectrometry assay for the determi- nation of platinum originating from cispla- tin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. J Mass Spectrom . 2006;41(9):1186-1194. doi:10.1002/jms.1087 21. Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 .; 2009. http://www.meddramsso.com . Accessed January 7, 2021. 22. West GB, Brown JH, Enquist BJ. A Gen - eral Model for the Origin of Allometric Scaling Laws in Biology. Science (80- ) . 1997;276(5309):122-126. 23. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM Users Guide - Part V. 24. Huiskamp LFJ, Chargi N, Devriese LA, May AM, Huitema ADR, de Bree R. The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis. J Clin Med . 2020;9(11):3780. doi:10.3390/jcm9113780 25. Cockcroft D, Gault M. Prediction of Creat - inine Clearance from Serum Creatinine. Nephron . 1976;16:31-41. 26. Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol . 2013;2(6):1-9. doi:10.1038/psp.2013.24 27. R Core Team. R: A Language and Environ - ment for Statistical Computing. 14